This content is restricted to IPO Boutique Subscribers Username or Email Password Remember me Lost your password? Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry[…]
06.23.20 Secondary Announcement
This content is restricted to IPO Boutique Subscribers Username or Email Password Remember me Lost your password? Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry[…]
Secondaries Announced 12.5.17
IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis. If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[…]
Secondaries Announce 3.15.17
THIS POST HAS BEEN INTENTIONALLY DELAYED TO 6PM IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received this information to their inbox on a REAL TIME basis. If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those[…]
High Profile Biotech, Editas Medicine, Set to Test IPO Market
The biotech barometer may be here. Editas Medicine (Nasdaq: EDIT), a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes, updated terms for its IPO and has scheduled a February 3rd trade date. The interest in this deal is currently very large for a few reasons. For[…]